Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of "Buy" by Analysts

Key Points

• Amneal Pharmaceuticals has received an average recommendation of "Buy" from five research analysts, with a 12-month price target of $12.00.
• Insider sales have occurred recently, including the Director John Kiely selling 32,000 shares and EVP Andrew S. Boyer selling 279,244 shares, indicating notable insider activity.
• Amneal Pharmaceuticals reported $0.23 earnings per share, surpassing expectations, and has set guidance for FY 2025 at 0.700-0.750 EPS.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has been given a consensus recommendation of "Buy" by the five research firms that are covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have covered the stock in the last year is $12.00.

A number of equities analysts recently weighed in on AMRX shares. The Goldman Sachs Group started coverage on shares of Amneal Pharmaceuticals in a research note on Friday, June 6th. They set a "buy" rating and a $12.00 target price for the company. JPMorgan Chase & Co. lifted their target price on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the stock an "overweight" rating in a research note on Tuesday.

Insider Activity at Amneal Pharmaceuticals

In related news, Director John Kiely sold 32,000 shares of the stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total transaction of $295,360.00. Following the transaction, the director directly owned 225,433 shares of the company's stock, valued at $2,080,746.59. This represents a 12.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrew S. Boyer sold 279,244 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the transaction, the executive vice president directly owned 152,426 shares in the company, valued at approximately $1,429,755.88. This represents a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 609,206 shares of company stock valued at $5,700,625 in the last ninety days. Insiders own 17.45% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Squarepoint Ops LLC lifted its stake in shares of Amneal Pharmaceuticals by 276.3% in the second quarter. Squarepoint Ops LLC now owns 572,548 shares of the company's stock valued at $4,632,000 after buying an additional 420,398 shares in the last quarter. Headlands Technologies LLC lifted its stake in shares of Amneal Pharmaceuticals by 570.1% in the second quarter. Headlands Technologies LLC now owns 24,692 shares of the company's stock valued at $200,000 after buying an additional 21,007 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Amneal Pharmaceuticals by 510.0% in the second quarter. Tower Research Capital LLC TRC now owns 17,768 shares of the company's stock valued at $144,000 after buying an additional 14,855 shares in the last quarter. State of Tennessee Department of Treasury bought a new position in shares of Amneal Pharmaceuticals in the second quarter valued at $133,000. Finally, Voleon Capital Management LP lifted its stake in shares of Amneal Pharmaceuticals by 33.8% in the second quarter. Voleon Capital Management LP now owns 62,065 shares of the company's stock valued at $502,000 after buying an additional 15,677 shares in the last quarter. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX opened at $9.79 on Tuesday. Amneal Pharmaceuticals has a 52-week low of $6.68 and a 52-week high of $10.34. The firm has a 50 day moving average price of $8.86 and a two-hundred day moving average price of $8.19. The stock has a market cap of $3.07 billion, a P/E ratio of 979.98 and a beta of 1.19.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Analysts predict that Amneal Pharmaceuticals will post 0.53 earnings per share for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.